TWI349007B - Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication - Google Patents

Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication

Info

Publication number
TWI349007B
TWI349007B TW093139922A TW93139922A TWI349007B TW I349007 B TWI349007 B TW I349007B TW 093139922 A TW093139922 A TW 093139922A TW 93139922 A TW93139922 A TW 93139922A TW I349007 B TWI349007 B TW I349007B
Authority
TW
Taiwan
Prior art keywords
piperidine
inhibitors
amino
respiratory syncytial
syncytial virus
Prior art date
Application number
TW093139922A
Other languages
English (en)
Other versions
TW200533669A (en
Inventor
Jean-Francois Bonfanti
Koenraad Jozef Lodewijk Andries
Frans Eduard Janssens
Francois Maria Sommen
Jerome Emile Georges Guillemont
Jean Fernand Armand Lacrampe
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34924150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI349007(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of TW200533669A publication Critical patent/TW200533669A/zh
Application granted granted Critical
Publication of TWI349007B publication Critical patent/TWI349007B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW093139922A 2003-12-18 2004-12-20 Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication TWI349007B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03104802 2003-12-18

Publications (2)

Publication Number Publication Date
TW200533669A TW200533669A (en) 2005-10-16
TWI349007B true TWI349007B (en) 2011-09-21

Family

ID=34924150

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093139922A TWI349007B (en) 2003-12-18 2004-12-20 Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication

Country Status (17)

Country Link
US (2) US7355051B2 (zh)
EP (1) EP1723136B1 (zh)
JP (1) JP2007514715A (zh)
KR (1) KR101074334B1 (zh)
CN (2) CN1894239A (zh)
AR (1) AR046771A1 (zh)
AT (1) ATE501135T1 (zh)
AU (1) AU2004298456B2 (zh)
BR (1) BRPI0417668A (zh)
CA (1) CA2548654C (zh)
DE (1) DE602004031776D1 (zh)
DK (1) DK1723136T3 (zh)
HR (1) HRP20110428T1 (zh)
MX (1) MXPA06007109A (zh)
RU (1) RU2381224C2 (zh)
TW (1) TWI349007B (zh)
WO (1) WO2005058873A1 (zh)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE353900T1 (de) * 2001-02-24 2007-03-15 Boehringer Ingelheim Pharma Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US8071583B2 (en) 2006-08-08 2011-12-06 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
UY32826A (es) 2009-08-04 2011-02-28 Takeda Pharmaceutical Compuestos heterocíclicos
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2012174312A2 (en) * 2011-06-15 2012-12-20 Glaxosmithkline Llc Benzimidazole derivatives as antiviral agents
EA030121B1 (ru) 2011-07-15 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные хиназолины, их получение и их применение в фармацевтических композициях
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
MA41614A (fr) * 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
MD3483164T2 (ro) 2017-03-20 2020-07-31 Forma Therapeutics Inc Compoziții pirolopirolice ca activatori ai piruvat kinazei (PKR)
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
CA1140119A (en) * 1978-04-03 1983-01-25 Joseph Torremans N-heterocyclyl-4-piperidinamines
US4556660A (en) 1982-07-12 1985-12-03 Janssen Pharmaceutica N.V. N-(Bicyclic heterocyclyl)-4-piperidinamines
US4634704A (en) 1983-10-06 1987-01-06 Janssen Pharmaceutica, N.V. Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines
KR100190299B1 (ko) * 1990-07-19 1999-06-01 디르크 반테 신규한 옥사졸릴 유도체
SK19122001A3 (sk) * 1999-06-28 2003-01-09 Janssen Pharmaceutica N. V. Inhibítory replikácie respiračného syncyciálneho vírusu
EP1418175A1 (en) * 1999-06-28 2004-05-12 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
AU774829B2 (en) * 1999-06-28 2004-07-08 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors

Also Published As

Publication number Publication date
US20070093659A1 (en) 2007-04-26
CA2548654C (en) 2012-08-07
TW200533669A (en) 2005-10-16
DK1723136T3 (da) 2011-06-27
KR20060117985A (ko) 2006-11-17
ATE501135T1 (de) 2011-03-15
WO2005058873A1 (en) 2005-06-30
US7355051B2 (en) 2008-04-08
CA2548654A1 (en) 2005-06-30
KR101074334B1 (ko) 2011-10-17
AR046771A1 (es) 2005-12-21
AU2004298456A1 (en) 2005-06-30
MXPA06007109A (es) 2006-08-23
DE602004031776D1 (de) 2011-04-21
EP1723136B1 (en) 2011-03-09
EP1723136A1 (en) 2006-11-22
HRP20110428T1 (hr) 2011-08-31
BRPI0417668A (pt) 2007-04-03
CN103450159A (zh) 2013-12-18
CN1894239A (zh) 2007-01-10
US20080146613A1 (en) 2008-06-19
RU2006125720A (ru) 2008-01-27
JP2007514715A (ja) 2007-06-07
RU2381224C2 (ru) 2010-02-10
AU2004298456B2 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
TWI349007B (en) Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
EG25799A (en) Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication
ZA200605893B (en) Aminobenzimidazones and benzimidazoles as inhibitors of respiratory syncytial virus replication
IL172876A0 (en) Substituted arylthiourea derivatives useful as inhibitors of viral replication
AP2064A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
IL177917A0 (en) Macrocyclic compounds as inhibitors of viral replication
PL352378A1 (en) Replication inhibitors of syncytial respiratory virus
DE60013836D1 (de) Replikationsinhibitoren des respiratorischen synzytialvirus
AU2003261434A8 (en) Iminothiazolidinones as inhibitors of hcv replication
PL352385A1 (en) Replication inhibitors of syncytial respiratory viruses
IL180488A0 (en) Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof of kinase inhibitors
IL180738A0 (en) Inhibitors of hcv replication
ZA200608798B (en) Macrocyclic compounds as inhibitors of viral replication
IL182054A0 (en) Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
EP1883619A4 (en) PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRAFLUOROBENZYLANILINE COMPOUND AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
EP1946007A4 (en) ANDROSTERONE DERIVATIVES AND METHODS OF USE
SI1753720T1 (sl) Postopek za pripravo perindoprila in njegovih soli
MY142783A (en) 5-or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
EP1900735A4 (en) PYRIDAZINYLAMINE DERIVATIVES, USE OF DERIVATIVES IN THE PREPARATION OF PICORNAVIRUS INHIBITORS
EP1776140A4 (en) METHOD FOR INHIBITING VIRAL REPLICATION
SI1723136T1 (sl) Piperidin-amino-benzimidazolni derivati kot inhibitorji replikacije respiratornega sincicijskega virusa
IL176063A0 (en) Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication
AP2006003487A0 (en) Substituted arylthiourea derivatives useful as inhibitors of viral replication.
IL191861A0 (en) Improved jasmonate derivatives, pharmaceutical compositions and methods of use thereof

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees